Biopharmaceutical company focused on developing therapies for neurological and endocrine-related diseases.
Neurocrine Biosciences, Inc. is a pioneering biopharmaceutical company dedicated to discovering, developing, and bringing to market innovative treatments for neurological, endocrine, and psychiatric disorders. With a diverse portfolio, the company addresses critical medical needs with therapies that include solutions for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside ongoing clinical programs across various therapeutic areas.
At the forefront of its offerings is INGREZZA, a VMAT2 inhibitor recognized as a leading treatment for tardive dyskinesia. Neurocrine Biosciences also boasts a range of commercial products such as ONGENTYS, designed as an adjunct therapy for Parkinson's disease alongside levodopa/DOPA decarboxylase inhibitors. Additionally, the company provides ORILISSA, targeting moderate to severe pain associated with endometriosis, and ORIAHNN, an oral non-surgical option for managing heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women.
The company's robust pipeline includes promising product candidates like NBI-921352, under development for pediatric and adult focal epilepsy indications, and NBI-827104, aimed at treating rare pediatric epilepsy and essential tremor. Neurocrine Biosciences is also advancing clinical programs for conditions such as major depressive disorder and schizophrenia with candidates like NBI-1065845, NBI-1065846, and NBI-118568.
Founded in 1992 and headquartered in San Diego, California, Neurocrine Biosciences operates with strategic partnerships and collaborations with industry leaders such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, and AbbVie Inc. Committed to advancing medical science and enhancing patient outcomes, the company continues to expand its global footprint while driving innovation in the field of biopharmaceuticals.